高级检索
当前位置: 首页 > 详情页

EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis

文献详情

资源类型:

收录情况: ◇ 统计源期刊 ◇ 北大核心 ◇ CSCD-C

机构: [a]State Key Laboratory of Oncology in South China, Guangdong 510060, China [b]Department of Medical Oncology, Sun Yat-se n University Cancer Center, Guangdong 510060, China
出处:
ISSN:

关键词: Epidermal growth factor receptor (egfr) Gene therapy Non-small cell lung cancer Target therapy Tumor necrosis factor-re lated apoptosis-in ducing ligand (trail)

摘要:
Apoptosis induced by tumor necrosis factor-re lated apoptosis -in ducing ligand (TRAIL) can be regulated by the epidermal growth factor (EGF) signaling pathway. In this study, recombinant adenoviral vectors that encode TRAIL gene from the hTERT/RGD promoter (AdTRAIL) was combined with drugs including gefitinib, elotinib, and cetuximab that inhibit EGFR and the EGF signaling pathway in non-small cell lung cancer (NSCLC) cell lines to investigate their antitumor activity. In vitro, compared to single reagent, AdTRAIL combined with EGFR inhibitors reduced proliferation and enhanced apoptosis in H460, A549, and SW1573 cell lines. Western blot results suggested that these effects were relative to up-regulation of pro-ap optosis protein BAX and down-re gulation of p-A KT. In vivo, AdTRAIL combined with cetuximab resulted in a significant growth reduction in H460 xenografts without damage to the main organs of nude mice. Histological examination and TUNEL analyses of xenografts showed that cetuximab enhanced cell apoptosis induced by AdTRAIL. These results indicate that EGFR inhibitors enhanced AdTRAIL anti-tu mor activity in NSCLC cell lines and that inhibiting the AKT pathway played an important role in this enhancement.

语种:
第一作者:
第一作者机构: [a]State Key Laboratory of Oncology in South China, Guangdong 510060, China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]非小细胞肺癌患者表皮生长因子受体突变对靶向治疗的疗效影响及生存分析 [2]非小细胞肺癌患者表皮生长因子受体突变对靶向治疗的疗效影响及生存分析 [3]A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer [4]A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2) [5]Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18 [6]Long-term safety of icotinib in patients with non-small cell lung cancer: A retrospective, real-world study(Open Access) [7]The Main Treatment Failure Pattern for Completely Resected Stage II-IIIA (N1-N2) EGFR-Mutation Positive Lung Cancer [8]Synergistic effect of canakinumab with epidermal growth factor receptor tyrosine kinase inhibitors versus with chemotherapy for non-small cell lung cancer [9]Safety, Efficacy and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients with EGFR-mutated Advanced NSCLC: a Multicenter, Open-label, Phase I Trial. [10]A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号